TRV
AGIO icon

Third Rock Ventures’s Agios Pharmaceuticals AGIO Stock Holding History

Third Rock Ventures’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-3,070,090
Closed -$344M – 5
2014
Q4 		$344M Hold
3,070,090
– – 28.13% 2
2014
Q3 		$188M Sell
3,070,090
-825,000
-21% -$35.6M 21.97% 2
2014
Q2 		$178M Sell
3,895,090
-1,669,324
-30% -$68M 38.11% 1
2014
Q1 		$218M Hold
5,564,414
– – 38.62% 1
2013
Q4 		$117M Buy
+5,564,414
New +$127M 33.07% 2

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CGT
Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Third Rock Ventures's AGIO Position: Q1 2015 in Review

Third Rock Ventures sold out of Agios Pharmaceuticals (AGIO) in Q1 2015, closing a stake of 3,070,090 shares — an estimated $344M sold.

Third Rock Ventures first reported a position in AGIO in Q4 2013 and held it in 5 quarters. The position peaked at $344M in Q4 2014. 152 funds tracked by Wall St. Rank hold AGIO as of Q1 2015.

  • Third Rock Ventures reported no remaining Agios Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Third Rock Ventures sold 3,070,090 Agios Pharmaceuticals shares in Q1 2015, an estimated $344M.
  • Third Rock Ventures first reported a position in Agios Pharmaceuticals in Q4 2013 and held it in 5 quarters.
  • Third Rock Ventures's Agios Pharmaceuticals position peaked at $344M in Q4 2014.
  • 152 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2015.

Based on Third Rock Ventures's 13F filing for Q1 2015, filed 29 Apr 2015.